FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367303035> ?p ?o ?g. }

• W4367303035 abstract "<h3>Objective:</h3> The purpose of this analysis is to gain insights into some of the challenges faced in a clinical setting when using magnetic resonance imaging (MRI) for the monitoring of multiple sclerosis (MS) disease activity. <h3>Background:</h3> MRI is considered by many to be the gold standard for the diagnosis and monitoring of MS. Imaging metrics are often the primary outcome measures for clinical trials assessing the efficacy of new treatments. While there have been significant technological advances in imaging techniques in research, practical application in a clinical setting has lagged for numerous reasons including cost and accessibility. Differences in equipment, sequence methodologies, and the interpretation can also affect the quality of the reports and the overall usefulness of MRI as a tool. <h3>Design/Methods:</h3> During a timeframe spanning 2020–2022, imaging metrics were collected from a database search of a single private practice with six practitioners in Salt Lake City, UT, USA serving several MS patients throughout the Intermountain West. <h3>Results:</h3> Approximately 200 brain MRI reports were input into the clinic database monthly with about 120 of those being ordered by directly by clinic and the remaining coming from referrals. In a single month, MRI images came from over 50 different facilities. Roughly 60% of those images were from the local hospital network, Intermountain Healthcare, which is comprised of over more than twenty different locations. Another 20% of scans came from the stand-alone imaging center, Mountain Medical Imaging, and another 20% of scans were from imaging centers representing less than 5% of the scans by volume. <h3>Conclusions:</h3> With an increasing number of MRI techniques and facilities available it is more important than ever for sites to be aware of the various factors that may affect the quality of imaging they use to evaluate and treat MS patients in their care. <b>Disclosure:</b> Ms. Hoyt has nothing to disclose. Ms. Christensen has a non-compensated relationship as a project manager with InterPro Bioscience that is relevant to AAN interests or activities. Ms. Roman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myer Squibb. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Ms. Roman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Ms. Roman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Ms. Roman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genzyme. Ms. Roman has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Ms. Roman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myer Squibb/Celgene. Mrs. Vivanco has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. Mrs. Vivanco has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Mrs. Vivanco has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Mrs. Vivanco has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Mrs. Vivanco has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave. Dr. Foley has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Foley has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Foley has stock in InterPRO Bioscience. The institution of Dr. Foley has received research support from Biogen. The institution of Dr. Foley has received research support from Novartis. The institution of Dr. Foley has received research support from Octave. The institution of Dr. Foley has received research support from Genentech. The institution of Dr. Foley has received research support from Imstem. The institution of Dr. Foley has received research support from Aegir." @default.
• W4367303035 created "2023-04-29" @default.
• W4367303035 creator A5008483440 @default.
• W4367303035 creator A5024583397 @default.
• W4367303035 creator A5027116773 @default.
• W4367303035 creator A5033188337 @default.
• W4367303035 creator A5048901568 @default.
• W4367303035 date "2023-04-25" @default.
• W4367303035 modified "2023-10-14" @default.
• W4367303035 title "The Challenges of MRI in Clinical Practice (P11-3.008)" @default.
• W4367303035 doi "https://doi.org/10.1212/wnl.0000000000204273" @default.
• W4367303035 hasPublicationYear "2023" @default.
• W4367303035 type Work @default.
• W4367303035 citedByCount "0" @default.
• W4367303035 crossrefType "proceedings-article" @default.
• W4367303035 hasAuthorship W4367303035A5008483440 @default.
• W4367303035 hasAuthorship W4367303035A5024583397 @default.
• W4367303035 hasAuthorship W4367303035A5027116773 @default.
• W4367303035 hasAuthorship W4367303035A5033188337 @default.
• W4367303035 hasAuthorship W4367303035A5048901568 @default.
• W4367303035 hasConcept C126838900 @default.
• W4367303035 hasConcept C143409427 @default.
• W4367303035 hasConcept C160735492 @default.
• W4367303035 hasConcept C162324750 @default.
• W4367303035 hasConcept C1862650 @default.
• W4367303035 hasConcept C19527891 @default.
• W4367303035 hasConcept C2779974597 @default.
• W4367303035 hasConcept C31601959 @default.
• W4367303035 hasConcept C40993552 @default.
• W4367303035 hasConcept C41008148 @default.
• W4367303035 hasConcept C50522688 @default.
• W4367303035 hasConcept C71924100 @default.
• W4367303035 hasConceptScore W4367303035C126838900 @default.
• W4367303035 hasConceptScore W4367303035C143409427 @default.
• W4367303035 hasConceptScore W4367303035C160735492 @default.
• W4367303035 hasConceptScore W4367303035C162324750 @default.
• W4367303035 hasConceptScore W4367303035C1862650 @default.
• W4367303035 hasConceptScore W4367303035C19527891 @default.
• W4367303035 hasConceptScore W4367303035C2779974597 @default.
• W4367303035 hasConceptScore W4367303035C31601959 @default.
• W4367303035 hasConceptScore W4367303035C40993552 @default.
• W4367303035 hasConceptScore W4367303035C41008148 @default.
• W4367303035 hasConceptScore W4367303035C50522688 @default.
• W4367303035 hasConceptScore W4367303035C71924100 @default.
• W4367303035 hasLocation W43673030351 @default.
• W4367303035 hasOpenAccess W4367303035 @default.
• W4367303035 hasPrimaryLocation W43673030351 @default.
• W4367303035 hasRelatedWork W122048475 @default.
• W4367303035 hasRelatedWork W1959086636 @default.
• W4367303035 hasRelatedWork W1984702375 @default.
• W4367303035 hasRelatedWork W1991265298 @default.
• W4367303035 hasRelatedWork W2076233556 @default.
• W4367303035 hasRelatedWork W2324367843 @default.
• W4367303035 hasRelatedWork W2411259504 @default.
• W4367303035 hasRelatedWork W2914748434 @default.
• W4367303035 hasRelatedWork W3143884343 @default.
• W4367303035 hasRelatedWork W4226512220 @default.
• W4367303035 isParatext "false" @default.
• W4367303035 isRetracted "false" @default.
• W4367303035 workType "article" @default.